Bio Synthesis Inc: Fill & Download for Free

Oligonucleotide Synthesis Market is Expected to Reach USD 8,200 Million in 2026 at a CAGR of 14.2%Chronic diseases are mostly an outcome of complex genetic interactions, environmental factors, and social factors. With the arrival of genetic testing, screening of birth defects and chronic diseases has become easier. Rising need for personalized medicine is increasing the demand for genetic models. Moreover, constantly growing genomics field in the quest of breakthrough technologies, require oligonucleotides product portfolio to grow. The technology is also not limited to healthcare, in future it is expected to penetrate diverse markets like personal wellness as well. The oligonucleotide is majorly used in the research application. Increasing R&D of DNA vaccines, rising application of gene therapy and gene screening of various diseases are the factors adding fuel to the market demand. For instance, the demand for Oligonucleotide is growing by 30% per year, American Chemical Society. Moreover, increasing association of pharma companies and research organization is also expanding its applications in different fields.Increasing Cases of Birth Defects to boost the demand for oligonucleotide in Research Activities in the Asia PacificGlobal oligonucleotide synthesis market by the Americas, Asia Pacific, Europe, & the Middle East and Africa. North America accounted for the largest share in 2018, followed by Europe. This has been achieved by the availability of most oligonucleotide-based drug approvals in these regions. Furthermore, the majority of oligonucleotide drugs are in pipeline and soon to enter the market are favoring the growth in future.Birth defects are one of the major causes of disability in developing countries. Studies have found that developing countries are lacking in terms of birth defects management. Despite the advent of the genomics era, BDRs in developing countries require changes on local and national levels, particularly in terms of low resource. Rare diseases affect approximately 6-8% of the population, an estimated 200 million people in the APEC region are living with one of the 7,000 known rare diseases of which 80% are genetic in origin, the Asia pacific economic corporation. In 2018, Asia pacific economic corporation established “APEC LSIF Rare Disease Network (RDN)” in the association with government, academia, and industry.In Australia, over 4,500 Australians are born with significant birth defects every year, the Australian Institute of Health and Welfare (AIHW). Moreover, a growing cancer population in the Asia Pacific is also an alarming situation. Asia is home to around half of the world’s new cases of cancer and cancer-related deaths. Around 17,500 people are diagnosed with cancer every day, a number is expected to reach around 25,000 by 2025, the ACCESS Health International. It’s estimated that around 190,000 new cases of prostate cancer are recorded annually and cause over 80,000 deaths, Johnson & Johnson. These life-threatening indications have led governments in the region to shift healthcare innovation like the U.S. and Europe.Got questions about your regional growth of Oligonucleotide Synthesis Market?Just drop us a line or call on +1 646 480 7505Government healthcare policies and growing research activities are creating favorable opportunities for oligonucleotide therapiesChina is positioning the country to be a potential leader in research and innovation. in 2017, China invested around USD 279 billion on R&D, and has an annual growth rate of 18.3% (2% of GDP), with a plan to invest over 4% of the GDP on the biotech sector by 2020, a report by Johnson & Johnson. Several countries in Asia are taking steps to implement universal health coverage. In 2018, the government of India announced a massive expansion of the country’s health insurance that, if implemented, will represent the world’s largest public health care program. In Indonesia, the government rolled out the national single-payer health care program, the Jaminan Kesehatan Nasional (JKN), with the goal of covering 240 million people by 2019, making it currently the largest universal health coverage program in the world.The Middle East and Africa are also experiencing significant growth due to the high prevalence of chronic diseases. In the last decade, the rise of chronic diseases in Africa has been inevitable and is expected to reach 42% by 2030, the WHO. However, growing investment and educational programs are expected to improve the situation.Key PlayersMerck KGaA offers DNA primers, probes and Next-Gen Sequencing Oligos for various life science applications. in 2018, it launched BioContinuum Platform for the manufacturing of biotherapeutic drug. Next-generation DNA synthesis is a key practice performed in research activity for various processes. The race to provide cheap, better and faster DNA synthesis is driving the competitiveness among players. To which, in 2017, SynBioBeta, raised USD 13 million from its key partner Illumina Ventures. The company is a renowned manufacturer of synthetic nucleic acids.Another prominent player Thermo Fisher Scientific entered into an agreement with BioNTech in February 2019. In this agreement, BioNTech's messenger RNA (mRNA) manufacturing platform will be supported by Thermo Fisher nucleotides, enzymes, and other critical raw materials.Some of the other leading players in the global oligonucleotide synthesis market are Integrated DNA Technologies, Inc., GenScript, Eurogentec, Eurofins, and Nitto Denko Corporation.Oligonucleotide Synthesis Market SegmentationBy Product TypeSynthesized Oligonucleotide ProductPrimersProbesLarge-scale Synthesis OligonucleotidesIntermediate-scale Synthesis OligonucleotidesOther Synthesized Oligonucleotide Product TypesReagentsEquipmentBy ApplicationResearchPCRQPCRSequencingGene SynthesisOther Research ApplicationDiagnosticsTherapeuticsRNAiNucleic Acid AptamersDNA/Antisense OligonucleotidesOther TherapeuticsBy End UserAcademic Research InstitutesPharmaceutical and Biotechnology CompaniesDiagnostic LaboratoriesRegions Covered:AmericaNorth AmericaU.S.CanadaMexicoSouth AmericaEuropeWestern EuropeUKGermanyFranceItalySpainRest of EuropeEastern EuropeAsia-PacificChinaIndiaJapanSouth KoreaAustraliaRest of Asia-PacificMEAThe Middle EastSaudi ArabiaUAEQatarRest of The Middle EastAfricaKey PlayersAgilent Technologies, Inc.ATDBio LtdTriLink BioTechnologies, LLCThermo Fisher ScientificNitto Denko CorporationMerck KGaALGC Biosearch TechnologieIntegrated DNA Technologies, Inc.GenScriptGE HealthcareEurogentecEurofinsBio-Synthesis

Here's a list from George's CV:George M. Church's Tech Transfer, Advisory Roles, and Funding Sources(short url for this page: v.ht/PHNc)The first date on each line indicates the year of company founding. (In parentheses are the dates & focus of my involvement.) Founder = F.Genome Sequencing: (see also Next-gen overview and current genome prices)Azco Biotech Oceanside CA 2003 (2009-present; sequencing system)Complete Genomics Sunnyvale CA 2006 (2006-present; Sequencing by Ligase service)Danaher-Dover-Polonator Salem NH 2007 (2007-present; sequencing instrument)IntelligentBioSystems (IBS, Qiagen) Waltham MA 2006 (2006-2012; Sequencing by Polymerase on beads)Lynx - Solexa - Illumina Hayward CA 1992; San Diego 1998 (2000-present; multiplex tags)LightSpeed Genomics Sunnyvale CA 2007 (2007-present; high-speed DNA sequencing)Noblegen Biosciences Boston MA 2010 (2010-2014; optipore sequencing)Genia Mountain View, CA (2011-present; then Roche; nanopores)Ion Torrent Guilford, CT 2008 (2009-2013; then LifeTech then Thermo Fisher ; electronic sequencing)IBM Yorktown Heights, NY 1911 (2009-2012) DNA Sequencing.NABsys Providence, RI 2005 (2010-present) SbH with nanopores.Genapsys 2010 (2010-present) label-free nanosensor array sequencing.Clinical and Consumer Genomic Diagnostics:AbVitro Boston MA 2010 (2010-present,F; Immunomes).Alacris Pharmaceuticals (Qiagen) Berlin 2008 (2008-present,F; Cancer genomics & systems biology)Androcyte Florida 2011 (2011-present; Supercentenarians)AOBiome Cambridge MA 2013 (2013-present; Skin Microbes)Ecoeos San Francisco 2013 (2013-present; Environmental chemicals and omics)Fitbiomics Boston MA 2015 (2015-present; Wellness genomics)Good Start Genetics Cambridge 2009 (2009-present; Molecular Diagnostics)Genomera San Francisco 2010 (2010-present; Crowd-sourced Health Insight)Knome, Inc. Cambridge MA 2007 (2007-present,F; Human Genome Sequencing)Med Data Quest (MDQ) San Diego CA 2015 (2015-present; Clinical genomics)Pathway Genomics San Diego CA 2008 (2013-present; Personal Genomics)ReadCoor Boston MA 2014 (2014-present,F; In situ Sequencing)Veritas Genetics Danvers MA 2015 (2015-present,F; Clinical Genomics)23andme Mountain View CA 2006 (2006-present; personal genomics)Synthetic Biology, Biofuels, Stem Cells & Therapeutics:BioViva Seattle WA 2015 (2015-present; anti-aging gene therapies)Caribou Biosciences Berkeley CA 2012 (2013-present; Cas9 tools)Celemics Korea 2011 (2011-present; Genome engineering.)Cellular Dynamics International (CDI) Madison WI 2006 (2009-present; iPS stem cells)Editas Cambridge MA 2013 (2013-present,F; Cas9 gene therapy)Egenesis Bio Boston MA 2013 (2013-present,F; Cas9 non-human applications)EnEvolv Cambridge MA 2011 (2011-present,F; genome engineering)Enzymatics Beverly MA 2006 (2006-present; Large-scale, high quality enzymes)Gen9 Cambridge MA 2009 (2009-present,F; Synthetic Biology)Genomatica San Diego CA 2001 (2001-present; microbial metabolic models)Genome Compiler Corp San Francisco CA 2011 (2011-present; Genome CAD)Joule Unlimited Cambridge MA 2007 (2007-present,F; SolarFuels)Pronutria 2011 (2011-present; nutritional synbio)Single Cell Technology San Jose CA 2013 (2013-present, Therapeutic antibodies)SeresHealth Cambridge MA 2012 (2012-present; microbiome therapeutics)Sigma-Aldrich St. Louis 1934 (2009-2015; chemistry, cells, Board of Directors)Transposagen Lexington KY 2003 (2014-present; Poseida Therapeutics, Hera Testing; Mammalian genome engineering)Warp Drive Biosynthetics Boston MA 2011 (2011-present,F; Natural product synthesis)Publishing and non-profit groups:Centre for Study of Existential Risk (CSER) Cambridge UK 2013 (2013-present; Risk)The Future of Life Institute (FLI) Cambridge MA 2014 (2014-present; technology risk management)pgEd Boston MA 2006 (2013-present; personal genetics education)Station for Natural Studies CT,MA 1986 (1986-present,F; genetics)Arc Boston MA 2014 (2014-present, Biomed + IT fusion)MindFirst Foundation Boston MA 2014 (2014-present,F; mental illnesses)PersonalGenomes.org Boston MA 2004 (2004-present,F; open-access genome & trait data)BioWeatherMap.org Boston MA 2009 (2009-present,F; DIYbio)X-prize.org Playa Vista CA 1996 (2005-present; sequencing & energy)Epstein Science Community and Epstein Foundations 1991 (2005-present; creative science community)Edge Foundation 1988 (2005-present; science communication)Scientific American 1845 (2008-present; editorial advisor)Nature Publishing Group (NPG) 1869 (2005-present; senior editor, MSB)Financial and Legal Consulting:evalueSCIENCE 2011 (2011-2013; Science and policy advising)Guidepoint Global (2009-2013; Genomics technologies)Gerson Lehrman Group (GLG) (2007-2013; Genomics technologies)DeMatteo Monness LLC 1997 (2011-2013; DNA Sequencing)ACLU (2009; DNA diagnostics)Supreme Court --Susman Godfrey LLP Amici Curiae Ebay & Half.com vs MercExchange LLC (2006; Intellectual Property)Companies licensing Church lab patents or software:Agilent Technologies Palo Alto 1999 (2001-present; nucleic acid nanopore sensors)Oxford NanoPore Technologies Kidlington UK 2005 (2008)Affymetrix (Affymax) Palo Alto CA 1993 (1990-2003; Oligonucleotide arrays)Agencourt (then Beckman Coulter) Beverly MA 2000 (2003-2006; Polony bead sequencing by ligation)Applied Biosystems Foster City CA 1981 (2003-2006; via Agencourt, polony bead sequencing by ligation)Pyrosequencing (also Biotage - 454) Stockholm 2000 (2001-2005; modified dNTPs for array sequencing)Millipore Bedford,MA (1989-1990; multiplex sequencing) and 2009-2013 via EMDCodon Devices (then Gen9) Cambridge MA 2005 (2005-2009,F; Constructive Biology)Mosaic Technologies (then Apogent, Illumina) Boston MA 1994 (1993-94 & 2000-2001; DNA diagnostics)Past Advisory roles:Pathogenica (then BioInnovation Solutions) Cambridge MA 2010 (2010-2014,F; Pathogencity and Drug resistance diagnostics)LS9 San Francisco CA 2005 (2006-2014,F; then REG Inc., Biologically engineered fuels)Telome Boston MA 2010 (2010-2014,F; Telomeres and aging)PharmoRx Wellesley MA 2005 (2005-2013; secure medication)Bionanomatrix Philadelphia PA 2008 (2009-2010; Fluorescent mapping)Cambrian Genomics 2011 (2011-2012; nextgen DNA synthesis + synthesis)DNAdirect MEDCO San Francisco CA 2004 (2006-2010; DNA diagnostics)Genizon Cantaloupe Quebec 2008 (2008-2010; In situ sequencing)Flagship Ventures Cambridge MA 2000 (2000-present; genomics & informatics)GreenFuel Technologies Corp. Cambridge MA 2004 (2005-2006; Photosynthetic CO2 emissions capture)Halcyon Molecular Redwood City CA 2009 (2009-2012; Mbp read-length EM sequencing)Pacific Biosciences Menlo Park CA 2004 (2008-2013; real-time single-molecule sequencing)Helicos Biosciences Corp Cambridge MA 2004 (2003-2012; Single-molecule DNA sequencing)HySeq Chicago 1993 (1993; Sequencing by Hybridization)Receptor Biologix (then Symphogen San Francisco CA 2003 (2004-2007; alternative splicing)Longenity Inc.; Boston MA 2001 (2001-2005; human aging)Xeotron (then Invitrogen) Houston TX 2000 Atactic (2001-2004; Light-directed DNA/RNA-microarray synthesis)Genome Pharmaceuticals (see GPC Biotech, Alacris) Martinsried, Germany 1998 (1998-2003; genomics for drug targets)Caliper Technologies (then PerkinElmer) Palo Alto CA 1995 (1994-2002; microfluidics)CodonCode Corp. Dedham MA 1996 (1996-2003); DNA sequencing software)NEB Beverly MA 1975 (2009-2010; protein synthesis)Qteros (formerly SunEthanol) Amherst MA 2007 (2007-2011; Biofuels)BeyondGenomics (then BGMedicine) Cambridge MA 2001 (2000-2004; biomarkers & systems biology)EngeneOS (leading to: Epitome, CodonDevices, Gen9) Cambridge MA 2001 (2000-2005; Engineered Genetic Operating Systems)GenProfile AG Berlin, Germany 1998 (1997-2001; multiplex haplotyping)Adeptient Los Altos, CA 2000 (2001-2002; inkjet aerosols for drug delivery and array manufacture)First Genetic Trust Chicago, IL 2001 (2001-2002; personal genetic information access)Sangamo (Gendaq) Richmond CA 1995 (2000-2002; Zn-finger engineering)Genome Therapeutics (Oscient & Agencourt, previously Collaborative Research Inc.) Waltham MA 1961 & 1993 (1984 & 1989-1994; microbial genomes)Biogen Inc. Cambridge, MA 1978 (1984-1985; genomic sequencing)Gamera (then Tecan LabCD) Medford MA 1995 (1998-2000; microfluidics)FamilyGenetix Oxford, UK (2000-2001; Genetic patient history software & services)Bruker Daltonics Billerica, MA 1960 (1993-1997; Mass-tags)Biorad-Sadtler Philadelphia PA (1979-1981; DNA sequencing software)Source:http://arep.med.harvard.edu/gmc/tech.html

Yes,absolutely. A synthetic cell,which can reproduce, completely controlled by man-made genetic instructions, had been created at a cost of $40 million,in the year 2010 by the researchers at the private J. Craig Venter Institute.Artificial gene synthesis, sometimes known as DNA printing is a method in synthetic biology that is used to create artificial genes in the laboratory. Currently based on solid-phase DNA synthesis, it differs from molecular cloning and polymerase chain reaction (PCR) in that the user does not have to begin with preexisting DNA sequences. Therefore, it is possible to make a completely synthetic double-stranded DNA molecule with no apparent limits on either nucleotide sequence or size. The method has been used to generate functional bacterial or yeast chromosomes containing approximately one million base pairs.Synthetic Genomics Inc., a company founded by Dr. Venter, provided $30 million to fund the experiments and owns the intellectual-property rights to the cell-creation techniques. The company has a $600 million contract with Exxon Mobil Corp. to design algae that can capture carbon dioxide and make fuel.To make the synthetic cell, a team of 25 researchers at labs in Rockville, Md., and San Diego, led by bioengineer Daniel Gibson and Mr. Venter, essentially turned computer code into a new life form. They started with a species of bacteria called Mycoplasma capricolum and, by replacing its genome with one they wrote themselves, turned it into a customized variant of a second existing species, called Mycoplasma mycoides, they reported.To begin, they wrote out the creature's entire genetic code as a digital computer file, documenting more than one million base pairs of DNA in a biochemical alphabet of adenine, cytosine, guanine and thymine. They edited that file, adding new code, and then sent that electronic data to a DNA sequencing company called Blue Heron Bio in Bothell, Wash., where it was transformed into hundreds of small pieces of chemical DNA, they reported.To assemble the strips of DNA, the researchers said they took advantage of the natural capacities of yeast and other bacteria to meld genes and chromosomes in order to stitch those short sequences into ever-longer fragments until they had assembled the complete genome, as the entire set of an organism's genetic instructions is called.They transplanted that master set of genes into an emptied cell, where it converted the cell into a different species.To set this novel bacterium—and all its descendants—apart from any natural creation, Dr. Venter and his colleagues wrote their names into its chemical DNA code, along with three apt quotations from James Joyce and others. These genetic watermarks will, eventually, allow the researchers to assert ownership of the cells.At least three other companies—Amyris Biotechnologies in Emeryville, Calif.; LS9 Inc. in San Francisco; and Joule Unlimited in Cambridge, Mass.—are working on the lines of Synthetic Genomics Inc.,(the company founded by Dr. Venter) synthetic cells to produce renewable fuels.